Cloning & Transgenesis
Open Access

Ahmed M Malki

Publications

• Editorial
  Novel Targeted Therapy for Lung Cancer: Revisited
  Author(s): Ahmed M Malki and Hassan A Aziz Ahmed M Malki and Hassan A Aziz
  
  Lung cancer accounts for about 27% of all cancer deaths and considered as the leading cause of cancer-associated death worldwide. Genotype-driven therapeutics is a standard of care for majority of subgroup of NSCLC patients with admetastatic disease. Recently, targeting NSCLC harboring anaplastic lymphoma kinase (ALK) fusions and ROS1 fusions have produced similar results in terms of overall response rate (ORR). Based on the fact that EGFR and ALK mutations are mutually exclusive, to the patients who carry ALK rearrangements are currently treated with an ALK inhibitor (crizotinib or ceritinib. BRAF targeting Tyrosine Kinase Inhibitors TKIs (dabrafenib, vemurafenib) are approved for BRAF mutated malignant melanoma and currently in phase III trials, the classical V600E mutation are most common and they occur within exons 11 and 15. BRAF V600E mutations are associated with light/never sm.. View More»
  DOI: 10.4172/2168-9849.1000e120

  Abstract PDF

Relevant Topics